CA2897618A1 - Process for making benzoxazepin compounds - Google Patents

Process for making benzoxazepin compounds Download PDF

Info

Publication number
CA2897618A1
CA2897618A1 CA2897618A CA2897618A CA2897618A1 CA 2897618 A1 CA2897618 A1 CA 2897618A1 CA 2897618 A CA2897618 A CA 2897618A CA 2897618 A CA2897618 A CA 2897618A CA 2897618 A1 CA2897618 A1 CA 2897618A1
Authority
CA
Canada
Prior art keywords
reacting
bromo
acid
cl2pd
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2897618A
Other languages
English (en)
French (fr)
Inventor
Remy Angelaud
Danial BEAUDRY
Diane CARRERA
Sushant Malhotra
Travis Remarchuk
Fredric ST-JEAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CA2948763A priority Critical patent/CA2948763C/en
Priority to CA2948765A priority patent/CA2948765A1/en
Publication of CA2897618A1 publication Critical patent/CA2897618A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2897618A 2013-03-13 2014-03-12 Process for making benzoxazepin compounds Abandoned CA2897618A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2948763A CA2948763C (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA2948765A CA2948765A1 (en) 2013-03-13 2014-03-12 Intermediate (4-bromo-2-fluorophenyl)-1h-imidazoyl derivatives for use in a process to synthesize benzoxazepin compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779619P 2013-03-13 2013-03-13
US61/779,619 2013-03-13
PCT/EP2014/054786 WO2014140073A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CA2948763A Division CA2948763C (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA2948765A Division CA2948765A1 (en) 2013-03-13 2014-03-12 Intermediate (4-bromo-2-fluorophenyl)-1h-imidazoyl derivatives for use in a process to synthesize benzoxazepin compounds

Publications (1)

Publication Number Publication Date
CA2897618A1 true CA2897618A1 (en) 2014-09-18

Family

ID=50241450

Family Applications (6)

Application Number Title Priority Date Filing Date
CA2897618A Abandoned CA2897618A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA2948765A Abandoned CA2948765A1 (en) 2013-03-13 2014-03-12 Intermediate (4-bromo-2-fluorophenyl)-1h-imidazoyl derivatives for use in a process to synthesize benzoxazepin compounds
CA2948763A Expired - Fee Related CA2948763C (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA3005112A Abandoned CA3005112A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA3005103A Abandoned CA3005103A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA3005118A Abandoned CA3005118A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds

Family Applications After (5)

Application Number Title Priority Date Filing Date
CA2948765A Abandoned CA2948765A1 (en) 2013-03-13 2014-03-12 Intermediate (4-bromo-2-fluorophenyl)-1h-imidazoyl derivatives for use in a process to synthesize benzoxazepin compounds
CA2948763A Expired - Fee Related CA2948763C (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA3005112A Abandoned CA3005112A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA3005103A Abandoned CA3005103A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA3005118A Abandoned CA3005118A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds

Country Status (15)

Country Link
US (1) US9303043B2 (https=)
EP (3) EP3845540A1 (https=)
JP (6) JP6363120B2 (https=)
KR (3) KR101871133B1 (https=)
CN (2) CN108929333A (https=)
AR (1) AR095365A1 (https=)
AU (3) AU2014230812B2 (https=)
BR (1) BR112015020716A2 (https=)
CA (6) CA2897618A1 (https=)
IL (1) IL240793A0 (https=)
MX (1) MX2015011438A (https=)
NZ (1) NZ711192A (https=)
RU (2) RU2018109979A (https=)
SG (2) SG10201706760YA (https=)
WO (1) WO2014140073A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180093138A (ko) 2013-12-16 2018-08-20 에프. 호프만-라 로슈 아게 2-(4-(2-(1-이소프로필-3-메틸-1H-1,2,4-트라이아졸-5-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)-1H-피라졸-1-일)-2-메틸프로판아미드의 다형체, 이의 제조 방법 및 이의 약학적 용도
AU2016287463B2 (en) 2015-07-02 2020-07-02 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
CN111848643A (zh) 2015-07-02 2020-10-30 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
CN105906635A (zh) * 2016-06-08 2016-08-31 上海大学 全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法
KR20190036549A (ko) * 2016-07-29 2019-04-04 니뽄 다바코 산교 가부시키가이샤 피라졸-아미드 화합물의 제조 방법
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018109204A1 (en) 2016-12-15 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide
CN108752237A (zh) * 2018-07-05 2018-11-06 四川青木制药有限公司 一种对氨基苯甲脒盐酸盐的新制备方法
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
WO2000024720A1 (en) * 1998-10-23 2000-05-04 Dow Agrosciences Llc 3-(substituted phenyl)-5-(substituted cyclopropyl)-1,2,4-triazole compounds
KR20040024564A (ko) 2001-07-12 2004-03-20 아베시아 리미티드 마이크로캡슐화된 촉매, 이의 제조 방법 및 이의 사용 방법
JP2005507932A (ja) * 2001-10-12 2005-03-24 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのフェニル置換５−員窒素含有複素環
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
BRPI0717320A2 (pt) * 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Triazóis bicíclicos como moduladores de proteína cinase
KR101083177B1 (ko) * 2006-10-23 2011-11-11 에스지엑스 파마슈티컬스, 인코포레이티드 트리아졸로-피리다진 단백질 키나제 조정제
JP2010516680A (ja) * 2007-01-19 2010-05-20 エックスカバリー，インコーポレイテッド キナーゼ阻害薬化合物
JP5348725B2 (ja) * 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
US8716483B2 (en) * 2008-02-21 2014-05-06 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
MX2010010659A (es) 2008-03-31 2010-10-26 Genentech Inc Compuestos de benzopirano y benzoxepina, inhibidores de fosfoinoinositida 3-cinasas y metodos para utilizarlos.
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US8263633B2 (en) 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
MY160064A (en) 2009-09-28 2017-02-15 Hoffmann La Roche Benzoxazepin pi3k inhibitor compounds and methods of use
WO2011053688A1 (en) * 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
CN102558167A (zh) * 2010-12-29 2012-07-11 中国医学科学院药物研究所 Gk和ppar双重激动活性的噻唑烷二酮衍生物
US9090628B2 (en) 2011-03-21 2015-07-28 Genentech, Inc. Benzoxazepin compounds selective for PI3K P110 delta and methods of use
NO3175985T3 (https=) * 2011-07-01 2018-04-28
BR112014028376A2 (pt) 2012-06-08 2018-04-24 Hoffmann La Roche métodos para o tratamento de um distúrbio hiperproliferativo, para a determinação dos compostos, para monitorar, para optimizar a eficácia terapêutica e de identificação de um biomarcador; formulação farmacêutica; utilização de uma combinação terapêutica e de gdc-0032, artigo de manufatura, produto e invenção

Also Published As

Publication number Publication date
KR101821468B1 (ko) 2018-01-23
EP3404032A2 (en) 2018-11-21
AU2014230812A1 (en) 2015-09-03
EP2970329A1 (en) 2016-01-20
JP2019031493A (ja) 2019-02-28
KR20150119033A (ko) 2015-10-23
JP6442005B2 (ja) 2018-12-19
EP3404032B1 (en) 2025-07-02
HK1215433A1 (zh) 2016-08-26
CA3005103A1 (en) 2014-09-18
JP6663459B2 (ja) 2020-03-11
JP2018008959A (ja) 2018-01-18
SG11201507394RA (en) 2015-10-29
RU2649976C2 (ru) 2018-04-06
EP3404032A3 (en) 2019-03-13
AU2018201393A1 (en) 2018-03-15
IL240793A0 (en) 2015-10-29
CN105377856B (zh) 2018-05-22
KR101871133B1 (ko) 2018-06-25
KR20180070715A (ko) 2018-06-26
AU2014230812B2 (en) 2016-04-07
AU2014230812A8 (en) 2015-09-10
RU2018109979A (ru) 2019-02-28
AU2016204432B2 (en) 2017-12-07
KR20170070270A (ko) 2017-06-21
CN105377856A (zh) 2016-03-02
JP6363120B2 (ja) 2018-07-25
CA3005112A1 (en) 2014-09-18
JP2019089762A (ja) 2019-06-13
EP3404032C0 (en) 2025-07-02
WO2014140073A1 (en) 2014-09-18
JP2020114814A (ja) 2020-07-30
RU2015138488A (ru) 2017-04-20
MX2015011438A (es) 2016-02-03
EP3845540A1 (en) 2021-07-07
AR095365A1 (es) 2015-10-14
CA2948765A1 (en) 2014-09-18
CA3005118A1 (en) 2014-09-18
AU2016204432A1 (en) 2016-07-21
US9303043B2 (en) 2016-04-05
CA2948763A1 (en) 2014-09-18
JP2018150298A (ja) 2018-09-27
US20140275523A1 (en) 2014-09-18
NZ711192A (en) 2019-04-26
BR112015020716A2 (pt) 2017-07-18
JP2016512209A (ja) 2016-04-25
SG10201706760YA (en) 2017-10-30
CN108929333A (zh) 2018-12-04
CA2948763C (en) 2018-04-24

Similar Documents

Publication Publication Date Title
AU2016204432B2 (en) Process for making benzoxazepin compounds
CA3154488A1 (en) Thyroid hormone receptor beta agonist compounds
KR101698283B1 (ko) 티에노피리미딘 화합물의 제조 방법
AU2013312931A1 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
CN111542526A (zh) 作为PI3K-γ抑制剂的由叔羟基取代的缩合咪唑衍生物
WO2018237134A1 (en) Atropisomerism for enhanced kinase inhibitor selectivity
CA2977752A1 (en) Benzimidazole compound for preventing or treating a disease caused by abnormal prs activity, method for preparing the same and pharmaceutical composition comprising the same
HK1215433B (zh) 制备苯并氧氮杂䓬化合物的方法
EA021781B1 (ru) 3-замещенные 6-(пиридинилметокси)пирролопиридиновые соединения
HK40119202A (zh) 杂环类sik抑制剂

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150709

FZDE Discontinued

Effective date: 20200312